Octapharma USA has appointed Baxter Bioscience's former VP of global marketing operations and haemophilia as its new VP of commercial development.
David Holliday will lead all US product marketing, sales and commercial activities at Octapharma, along with co-ordinating its global portfolio development initiatives.
The company is the US affiliate of Swiss-headquartered Octapharma AG, which develops and manufactures human protein products.
Holliday spent eight years at Baxter, gaining US and international experience in management, sales, marketing and business development, and was responsible for several successful product launches.
Prior to his time at Baxter, he held leadership positions at both Novartis and Ciba-Geigy Pharmaceuticals.
“We are very excited to have David Holliday, a true global leader in our industry, join our senior management team,” said Octapharma's USA president, Flemming Nielsen.
“He joins Octapharma USA at an extremely important time for our company as our product portfolio in the US will be increasing significantly in the next year and we expect David will be integral to our growth.”
No results were found
Genesis Research is an international HEOR and RWE research organization. A leader in evidence strategy, generation and communication, the company...